The predictive significance of CD20 expression in B-cell lymphomas

Diagnostic Pathology

Volumn 6, Issue 1, 2011, Pages

  Prevodnik, Veronika K ^a   Lavrenčak, Jaka ^a   Horvat, Mateja ^b   Novakovič, Barbara J ^a  

^a INSTITUTE OF ONCOLOGY   (Slovenia)

^b doo   (Slovenia)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; TUMOR MARKER;

ARTICLE; B CELL LYMPHOMA; FLOW CYTOMETRY; HUMAN; IMMUNOPHENOTYPING; METABOLISM; MORTALITY; PROGNOSIS; SLOVENIA; SURVIVAL RATE;

ANTIGENS, CD20; FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; LYMPHOMA, B-CELL; PROGNOSIS; SLOVENIA; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 79955469821     PISSN: None     EISSN: 17461596     Source Type: Journal    
DOI: 10.1186/1746-1596-6-33     Document Type: Article

References (16)

1. Jezeršek Novaković B, Kotnik V, Južnič Šetina T, Vovk M, Novaković S. Testing of mechanisms of action of R and clinical results in high-risk patients with aggressive CD20+ lymphoma. Radiol Oncol 2007, 41(1):23-32.
2. Cheson BD, Leonard JP. Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma - Review. N Engl J Med 2008, 359(6):613-26. 10.1056/NEJMra0708875, 18687642.
3. Ginaldi L, De Martinis M, Matutes E, Farahat N, Morilla R, Catovsky D. Levels of expression of CD19 and CD20 in chronic B cell leukaemias. J Clin Pathol 1998, 51(5):364-9. 10.1136/jcp.51.5.364, 500695, 9708202.
4. Olejniczak SH, Stewart CC, Donohue K, Czuczman MS. A quantitative exploration of surface antigen expression in common B-cell malignancies using flow cytometry. Immunol Invest 2006, 35(1):93-114. 10.1080/08820130500496878, 16531332.
5. Huh YO, Keating MJ, Saffer HL, Jilani I, Lerner S, Albitar M. Higher levels of surface CD20 expression on circulating lymphocytes compared with bone marrow and lymph nodes in B-cell chronic lymphocytic leukemia. Am J Clin Pathol 2001, 116(3):437-43. 10.1309/438N-E0FH-A5PR-XCAC, 11554173.
6. Hennessy BT, Hanrahan EO, Daly PA. Non-Hodgkin lymphoma: an update. Lancet Oncol 2004, 5(6):341-53. 10.1016/S1470-2045(04)01490-1, 15172354.
7. Lin P, Owens R, Tricot G, Wilson CS. Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. Am J Clin Pathos 2004, 121:482-88.
8. Horvat M, Kloboves Prevodnik V, Lavrenčak J, Jezeršek Novakovič B. Predictive significance of the cut-off value of CD20 expression in patients with B-cell lymphoma. Oncol Rep 2010, 24(4):1101-7.
9. Johnson NA, Boyle M, Bashashati A, Leach S, Brooks-Wilson A, Sehn LH, et al. Diffuse large B cell lymphoma: reduced CD20 expression is associated with an inferior survival. Blood 2009, 113(16):3773-80. 10.1182/blood-2008-09-177469, 2943836, 19029441.
10. Primic-Žakelj M. Epidemiologija in register raka v Sloveniji, Incidenca raka v Sloveniji 2006. 2009, Ljubljana: Onkološki inštitut.
11. Swerdlow AJ. Epidemiology of Hodgkin's disease and non-Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging 2003, 30(Suppl 1):S3-12. 10.1007/s00259-003-1154-9, 12734687.
12. Kloboves-Prevodnik V, Fležar M, Pohar-Marinšek T. Improved method for flow cytometric immunophenotyping of FNAB samples (abstract). XXII ISAC international congress 2004, 14. Montpellier: International society for analytical cytology.
13. Schwartz A, Gaigalas AK, Wang L, Marti GE, Vogt RF, Fernandez-Repollet E. Formalization of the MESF unit of fluorescence intensity. Cytometry part B (Clinical Cytometrey) 2004, 57B:1-6.
14. Marcus R, Hagenbeek A. The therapeutic use of R in non-Hodgkin's lymphoma. Eur J Haematol Suppl 2007, 67:5-14. 10.1111/j.1600-0609.2006.00789.x, 17206982.
15. Fanale MA, Younes A. Monoclonal antibodies in the treatment of non-Hodgkin lymphoma. Drugs 2007, 67(3):333-50. 10.2165/00003495-200767030-00002, 17335294.
16. Hagemeister F. Rituximab for the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Drugs 2010, 70(3):261-72. 10.2165/11532180-000000000-00000, 20166765.